Artelo biosciences reports fiscal 2021 year-end financial results and provides business update

$26.8 million in cash and marketable securities as of november 15, 2021, expected to support operations well into 2023 $26.8 million in cash and marketable securities as of november 15, 2021, expected to support operations well into 2023
ARTL Ratings Summary
ARTL Quant Ranking